Eyebiotech Funding: $130M Raised, Series A (2023)

Eyebiotech is based in San Francisco, California. It has raised $130M in total funding. Latest round: Series A.

Eyebiotech funding overview

Eyebiotech is based in San Francisco, California. Eyebiotech has raised $130M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in November 2023. The round record for Eyebiotech runs through 2023; nothing later has been disclosed. Investors on record include SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures Fund, Bain Capital Life Sciences, Omega Funds and 1 others. 7 distinct backers are named across the disclosed rounds.

Eyebiotech at a glance

Total raised
$130M
Latest round
Series A
Latest round date
November 2023
Headquarters
San Francisco, California
Notable investors
SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures Fund, Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC

Frequently asked about Eyebiotech funding

How much has Eyebiotech raised?
Eyebiotech has raised $130M in total disclosed funding across the rounds on record.
Who has invested in Eyebiotech?
SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures Fund, Bain Capital Life Sciences, Omega Funds are named among the investors backing Eyebiotech.
What was the latest Eyebiotech funding round?
The most recent disclosed round is a Series A, announced in November 2023.
Where is Eyebiotech based?
Eyebiotech is based in San Francisco, California.
When did Eyebiotech last raise?
The last disclosed Eyebiotech round closed in November 2023 at Series A.

Every Eyebiotech figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in San Francisco at a similar stage.

Companies related to Eyebiotech (36)

Browse related funding lists (10)

Company funding database · Investor directory · Founder database · Mega-rounds 2026